Updated Views in Targeted Therapy in the Patient with Non-Small Cell Lung Cancer

• Published in: Journal of personalized medicine Vol. 13; no. 2; p. 167
• Main Authors: Ortega, Miguel A, Pekarek, Leonel, Navarro, Fátima, Fraile-Martínez, Oscar, García-Montero, Cielo, Álvarez-Mon, Miguel Ángel, Diez-Pedrero, Raúl, Boyano-Adánez, María Del Carmen, Guijarro, Luis G, Barrena-Blázquez, Silvestra, Gómez-Lahoz, Ana M, Haro, Sergio, Arroyo, Mónica, Monserrat, Jorge, Saez, Miguel A, Alvarez-Mon, Melchor
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 17.01.2023; MDPI
• Subjects: Adenocarcinoma; Analysis; Cancer therapies; Care and treatment; Cell cycle; Chemotherapy; Crizotinib; Health aspects; Life span; Lung cancer; Lung cancer, Non-small cell; Lung cancer, Small cell; Medical prognosis; Metastasis; Mortality; Non-small cell lung carcinoma; Patients; Precision medicine; Prognosis; Review; Risk factors; Small cell lung carcinoma; Squamous cell carcinoma; Therapeutic targets; Thoracic surgery; Tobacco; Tumors; Women; Spain; pulmonary squamous cell carcinoma; large cell carcinoma; non-small cell lung carcinoma; immunotherapy; lung adenocarcinoma
• ISSN: 2075-4426; 2075-4426
• DOI: 10.3390/jpm13020167

Non-small cell lung cancer (NSCLC) is the most frequent form of lung cancer and represents a set of histological entities that have an ominous long-term prognosis, for example, adenocarcinoma, squamous carcinoma and large cell carcinoma. Both small cell and non-small cell lung cancer are the main causes of oncological death and the oncological diseases with the highest incidence worldwide. With regard to clinical approaches for NSCLC, several advances have been achieved in diagnosis and treatment; the analysis of different molecular markers has led to the development of new targeted therapies that have improved the prognosis for selected patients. Despite this, most patients are diagnosed in an advanced stage, presenting a limited life expectancy with an ominous short-term prognosis. Numerous molecular alterations have been described in recent years, allowing for the development of therapies directed against specific therapeutic targets. The correct identification of the expression of different molecular markers has allowed for the individualization of treatment throughout the disease course, expanding the available therapeutic arsenal. The purpose of this article is to summarize the main characteristics of NSCLC and the advances that have occurred in the use of targeted therapies, thus explaining the limitations that have been observed in the management of this disease.